HUMAN and Wantai Join Forces in the Fight Against COVID-19

To meet the worldwide demand for specific and sensitive SARS CoV-2 antibody tests, HUMAN Gesellschaft für Biochemica und Diagnostica mbH has signed a global distribution agreement with Beijing Wantai BioPharm, one of the leading manufacturers of diagnostics for infectious diseases.

With partners in more than 160 countries, HUMAN is considered a global player in the IVD industry and therefore represents an ideal distribution partner.

The agreement comprises a total Ab ELISA, an IgM specific ELISA and a total Ab rapid test. Both total Ab tests cover the detection of IgM, IgA and IgG antibodies.
The tests have been clinically evaluated in many countries, including Europe, and show leading performance as stated in several publications [1,2,3]. Wantai has developed the tests using the S1 subunit of the Receptor Binding Protein (RDB). The RDB is the main target antigen for virus neutralising antibodies, which may indicate a potential immunity.

Although RT-PCR is the recommended in most countries for diagnosis of a SARS-CoV-2 infection, antibody tests are especially important for detecting previous infections in people who had few or no symptoms.
In addition, numerous other parameters show abnormal laboratory results in COVID-19 patients and can be used for triage and monitoring.

These are especially haematology parameters, like lymphocyte counts, a series of clinical chemistry parameters like CRP, as well as D-Dimer in coagulation.

The special COVID-19 section on the HUMAN website not only provides the most important information on the two antibody test solutions. The latest webinars and a list of the most important COVID-19 publications can be also accessed there. The fact sheets on accompanying diagnostics conclude the content.

More information online

References

1. Lassaunière R. et al. (2020): Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxriv. https://doi.org/10.1101/2020.04.09.20056325

2. Herroelen P.H. et. al. (2020): Kinetics of the humoral immune response to SARS-CoV-2: comparative analytical performance of seven commercial serology tests. medRxiv. https://doi.org/10.1101/2020.06.09.20124719

3. GeurtsvanKessel CH. Et al. (2020): Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment. medRxiv. https://doi.org/10.1101/2020.04.23.20077156